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Objectives This study sought to evaluate the outcomes of radiofrequency catheter ablation (RFA) of ventricular tachycardia
(VT) in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) patients. Particular focus was
placed on defining the single-procedure efficacy over long-term follow-up.
Background ARVD/C is an inherited cardiomyopathy characterized by VT and right ventricular dysfunction. Prior single-center
studies have reported conflicting results concerning the efficacy of RFA of VT in ARVD/C patients.
Methods The study population comprised 24 patients (age 36  9 years, 11 male), enrolled in the Johns Hopkins ARVD
registry, who underwent 1 or more RFA procedures for treatment of VT. Patients were followed up for 32  36
months (range 1 day to 12 years). Recurrence was defined as the documentation of VT subsequent to the
procedure.
Results A total of 48 RFA procedures were performed using 3-dimensional electroanatomical (n  10) or conventional
(n  38) mapping. Of these procedures, 22 (46%), 15 (31%), and 11 (23%) resulted in elimination of all induc-
ible VTs, clinical VT but not all, and none of the inducible VTs, respectively. Forty (85%) procedures were followed
by recurrence. The cumulative VT recurrence-free survival was 75%, 50%, and 25% after 1.5, 5, and 14 months,
respectively. The cumulative VT recurrence-free survival did not differ by procedural success, mapping technique,
or repetition of procedures. There was 1 procedure-related death.
Conclusions Our study shows a high rate of recurrence in ARVD/C patients undergoing RFA of VT. This likely reflects the fact
that ARVD/C is a diffuse cardiomyopathy with progressively evolving electrical substrate. Further studies are
needed to define the precise role of RFA of VT in ARVD/C. (J Am Coll Cardiol 2007;50:432–40) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.049d
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crrhythmogenic right ventricular dysplasia/cardiomyopathy
ARVD/C) is an inherited cardiomyopathy characterized by
rogressive fibro-fatty replacement of the right ventricular
RV) myocardium (1,2). Recurrent ventricular tachycardia
VT) and sudden cardiac death are clinical hallmarks of the
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007, accepted March 20, 2007.isease (3,4). Scar tissue within the myocardium may be
ultifocal or diffuse, and provides a substrate for re-entrant
T (5,6). Recent studies have shown that ARVD/C results
rom mutations in genes encoding desmosomal proteins (7).
t has been hypothesized that altered desmosomal proteins
mpair cell-to-cell adhesion that results in cellular uncou-
ling and lead to fibro-fatty replacement of myocytes.
Because patients with ARVD/C are at significantly in-
reased risk of sudden death, most patients diagnosed with
his disease, especially in the U.S., undergo implantable
ardioverter-defibrillator (ICD) implantation. Multiple
tudies have reported a high rate of appropriate ICD firing
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July 31, 2007:432–40 VT Ablation in ARVD/Cmong patients with ARVD/C (4,8–11). Consequently,
djunctive treatment with antiarrhythmic drug therapy
nd/or radiofrequency catheter ablation (RFA) is commonly
ecommended. Several single-center studies have reported
onflicting results concerning the acute and long-term
fficacy of radiofrequency catheter ablation in patients with
RVD/C (12–18). Interpretation of the results of these
tudies also is complicated by variable adherence to the
nternational Task Force definition of ARVD/C (19) for
nrollment, variable use of repeat ablation procedures,
efinitions of “success,” and marked differences in the
uration of follow-up.
The purpose of this study was to investigate the long-
erm results of catheter ablation of VT performed in
RVD/C patients enrolled in the Johns Hopkins ARVD/C
egistry. Each of the enrolled patients met the strict criteria
or ARVD/C diagnosis as defined by the International Task
orce.
ethods
tudy population. The Johns Hopkins ARVD registry was
stablished in 1999 with the goal of gaining insights into the
iagnosis, genetic basis, and clinical course of patients with
nown or suspected ARVD/C. All patients included in this
egistry provided written informed consent to participate in
he registry and are contacted at yearly intervals to deter-
ine their clinical course. The patient population screened
or inclusion in this study was composed of 24 registry
articipants who met the Task Force Definition of
RVD/C and had undergone 1 or more attempts at RFA.
ach patient had previously experienced 1 or more episodes
f sustained VT. The study protocol was approved by the
ohns Hopkins Medicine Institutional Review Board.
A total of 48 catheter ablation procedures were preformed
n the 24 patients included in this report. These procedures
ere performed in 29 different electrophysiology centers
cross the U.S. Medical history was elicited by patient
nterview and a detailed review of the patient’s medical
ecords. Therapeutic decisions were made by the treating
lectrophysiologist in conjunction with each patient. Proce-
ure reports and ICD interrogation reports were obtained
irectly from the treating electrophysiologists and reviewed
t our center.
lectrophysiology study, mapping, and ablation tech-
ique. Electrophysiology testing and radiofrequency cath-
ter ablation were performed using standard techniques
20). Clinical VT(s) were defined by several techniques,
ncluding a comparison of 12-lead electrocardiographic
orphologies of induced and spontaneous VT, and when a
2-lead electrocardiogram of the clinical VT was not avail-
ble, by comparison of induced and spontaneous VT cycle
engths and/or intracardiac electrogram morphologies.
lectroanatomical mapping was used to facilitate ablation
uring 10 procedures in 6 patients (21,22). All other
blation procedures were performed using conventional Iapping and ablation techniques
ncluding pace mapping, activa-
ion mapping, and entrainment
apping (23).
Standard radiofrequency en-
rgy delivered through 4-mm
ipped deflectable ablation cath-
ters was used for each of the
blation procedures. Ablation of
particular morphology of VT
as considered successful if it
ould not be induced on repeated
timulation. Procedural success
as defined as total when all of
he inducible VTs could be successfully mapped and ab-
ated, partial when not all of the inducible VTs were
uccessfully ablated but the clinical VT was successfully
blated, and failure if none of the inducible VTs could be
blated successfully.
ollow-up. Patients were followed up routinely in clinics
y their treating electrophysiologists. At the same time, they
ere contacted at yearly intervals by our center. Implantable
ardioverter-defibrillator interrogation reports from patients
ith ICDs were sent to our center by the patient and/or the
reating electrophysiologist. Appropriateness of ICD inter-
ention was defined using the standard criteria (10). The
T recurrence was defined as an appropriate ICD interven-
aseline Characteristics of the Patients
Table 1 Baseline Characteristics of the Patients
Characteristics n  24
Age (yrs) at the time of the first procedure, mean  SD 36 9
Gender, male 11 (46)
ICD implantation
Before the first ablation procedure 5 (21)
During follow-up 14 (58)
No ICD 5 (21)
Previously failed antiarrhythmics
Beta-blockers 8 (33)
Sotalol 5 (21)
Amiodarone 3 (13)
Flecainide 2 (8)
Mexilitine 2 (8)
Calcium channel blockers 2 (8)
Propafenone 2 (8)
Procainamide 1 (4)
Quinidine 1 (4)
Disopyramide 1 (4)
Antiarrhythmics at the time of catheter ablation (n  48)
Beta-blockers 15 (32)
Sotalol 11 (23)
Amiodarone 9 (19)
Flecainide 5 (10)
Calcium channel blockers 3 (6)
Mexilitine 2 (4)
Procainamide 1 (2)
Dofetilide 1 (2)
Abbreviations
and Acronyms
ARVD/C  arrhythmogenic
right ventricular
dysplasia/cardiomyopathy
ICD  implantable
cardioverter-defibrillator
RFA  radiofrequency
catheter ablation
RV  right
ventricle/ventricular
VT  ventricular
tachycardiaCD  implantable cardioverter-defibrillator.
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VT Ablation in ARVD/C July 31, 2007:432–40ion or the occurrence of VT subsequent to the ablation
rocedure as documented by a 12-lead electrocardiogram,
n event monitor, or a 24-h Holter monitor. The time to
T recurrence after each ablation procedure was noted.
ong-term success was defined as the absence of recurrence
f VT over follow-up.
tatistical analysis. Continuous variables are expressed as
ean  SD, and categorical variables as frequency (%).
vent was defined as VT recurrence after the ablation
rocedure. Follow-up time was calculated from the time of
rocedure and censored at the occurrence of an event, loss of
ollow-up, or heart transplantation. Kaplan-Meier survival
nalysis was used to determine the cumulative recurrence-
ree survival in the study population.
Thirteen of the 24 patients in the study population
nderwent more than 1 ablation procedure because of VT
ecurrence subsequent to the initial ablation procedure. To
nclude the subsequent procedures in the survival analysis, a
taggered entry approach was used. These individuals
ho had more than 1 procedure re-entered the survival
nalysis after their initial recurrence and were followed up
ntil they experienced an event or were censored again.
his process was repeated for each time that a new
atheter ablation procedure was performed on the same
atient. Comparisons in the cumulative event-free sur-
ival between patients with total procedural success
ersus partial procedural success versus procedural failure,
atients undergoing mapping of VT using 3-dimensional
lectroanatomical mapping versus traditional mapping
ask Force Criteria in the Study Population
Table 2 Task Force Criteria in the Study Population
No. Structural Depolarization Repola
1 Major Major Mi
2 Major Major Mi
3 Major Major Mi
4 Minor Minor Mi
5 Minor Major No
6 Minor None Mi
7 Major None No
8 Minor Minor No
9 Major Major Mi
10 Minor Minor Mi
11 Major Major Mi
12 Minor Major Mi
13 Major Major Mi
14 Minor Major Mi
15 Major Major Mi
16 Minor Major Mi
17 Minor Minor Mi
18 Major None Mi
19 Major None Mi
20 Major Minor Mi
21 Minor Minor Mi
22 Minor Major Mi
23 Minor Minor Mi24 Major Major Minorechnique, and initial versus repeat ablation procedures
ere made using the log-rank test.
All statistical analyses were performed using STATA
tatistical software (version 8.2, 1984, StataCorp, College
tation, Texas). A p value of 0.05 was considered statis-
ically significant.
esults
tudy population. The study population comprised 24
RVD/C patients who underwent catheter ablation for
T. Table 1 shows baseline characteristics of the study
opulation. The mean age at their first procedure was 36 
years. Eleven (46%) of the 24 patients were male. Five
21%) of the patients had an ICD implanted before their
rst catheter ablation procedure, 14 (58%) had an ICD
mplanted during follow-up, and 5 (21%) did not have an
CD implanted at the end of follow-up. Table 2 shows the
scertainment of the Task Force criteria in each of the 24
atients. There was no or minimal left ventricular involve-
ent in the patients.
lectrophysiology study, mapping, and ablation. Table 3
hows the electrophysiological details of each of the 48
rocedures. Consistent with the entry criteria for this
tudy, all patients had VT induced during baseline
lectrophysiological testing. More than 1 distinct VT
orphology was induced in 37 (77%) of the procedures.
apping of the VT was performed using 3-dimensional
lectroanatomical mapping during 10 (21%) of the abla-
ion procedures.
n Arrhythmia Tissue Family History
Minor — None
Minor — None
Minor — None
Minor — None
Minor — None
Minor Major None
Minor Major None
Minor None None
Minor Major None
Minor — None
Minor — None
Minor — None
Minor — None
Minor — Minor
Minor — None
Minor — None
Minor None None
Minor None None
Minor Major None
Minor Major None
Minor — None
Minor Major None
Minor None Minorrizatio
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nor
nor
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July 31, 2007:432–40 VT Ablation in ARVD/CRadiofrequency energy was applied to ablate the VT in
ach of these procedures. In 11 (23%) of the 48 procedures,
he clinical VT was inducible after ablation, whereas in the
emaining 37 (77%) procedures, the clinical VT was suc-
etails of Electrophysiology Catheter Ablation Procedure and VT R
Table 3 Details of Electrophysiology Catheter Ablation Procedu
No. Age (yrs) Gender Abl Mapping VT Induced VT Abla
1 37 Male 1 Conv 4 4
41 2 Conv 2 1
2 41 Female 1 Conv 2 1
42 2 Conv 4 1
47 3 Conv 4 3
3 26 Male 1 Conv Multiple 1
27 2 Conv Multiple 1
29 3 Conv Multiple 0
33 4 3D 2 2
4 29 Female 1 Conv 1 1
29 2 Conv 1 1
30 3 Conv 1 1
30 4 3D 1 1
33 5 Conv 3 3
5 57 Female 1 Conv 2 1
58 2 Conv 3 0
6 35 Male 1 Conv 5 1
35 2 Conv 5 0
35 3 Conv 11 2
35 4 3D 4 4
35 5 3D 1 1
7 38 Female 1 Conv 4 0
8 40 Female 1 Conv 3 3
42 2 Conv 1 1
43 3 Conv 2 2
9 56 Male 1 Conv Multiple 1
10 22 Male 1 3D 1 1
22 2 3D 3 3
11 38 Male 1 Conv Multiple 6
39 2 Conv 5 3
12 42 Female 1 Conv 1 1
13 26 Female 1 Conv 3 3
31 2 3D Multiple 0
14 32 Female 1 Conv 3 3
33 2 Conv 2 2
15 23 1 Conv 4 4
16 32 Male 1 3D 5 3
33 2 3D 6 3
33 3 3D Multiple 0
17 39 Male 1 Conv Multiple 0
18 31 Female 1 Conv 1 0
19 42 Female 1 Conv 1 1
20 45 Male 1 Conv 3 0
21 31 Female 1 Conv 2 2
34 2 Conv 3 1
22 28 Male 1 Conv 2 0
23 51 Male 1 Conv 3 2
24 30 Female 1 Conv 1 1
Indicates drugs at last follow-up. No recurrence was noted at last contact. †Patient died as a co
3D  3-dimensional electroanatomical; Abl  attempt at ablation; Amio  amiodarone; -bl
ecainide; ICD  implantable cardioverter-defibrillator; Met  metoprolol; Mex  mexiletine; Proessfully ablated and could not be re-induced with pro- prammed electrical stimulation. All of the induced VTs
ere ablated in 22 (46%) of the 48 procedures. Thus, total
rocedural success was seen in 46%, partial procedural
uccess in 31%, and procedural failure in 23% of the
ence
d VT Recurrence
Clinical VT
Ablated ICD Rec Drugs at Ablation Drugs at Recurrence
Yes No Yes None None
Yes No Yes None None
Yes No No None None*
Yes Yes Yes None Sot
Yes Yes Yes Sot Flec, -bloc
Yes Yes Yes None Amio, -bloc
Yes Yes Yes Coum, Sot Coum, Sot
No Yes Yes Amio, -bloc Amio, -bloc
Yes Yes Yes Amio, -bloc Amio, -bloc
Yes No Yes None None
Yes No Yes None -bloc
Yes No Yes -bloc -bloc
Yes No Yes Amio Amio, -bloc
Yes Yes Yes Flec, -bloc, CCB Flec, -bloc, CCB
Yes No Yes CCB -bloc
No Yes Yes -bloc -bloc
Yes Yes Yes Met Met
No Yes Yes Met Met
Yes Yes Yes Met, Mex, Proc Amio, Met, Mex
Yes Yes Yes -bloc, Mex Mex
Yes Yes Yes Mex Mex
No Yes Yes None -bloc
Yes No No None None*
Yes No Yes None None
Yes No No Sot Sot*
Yes Yes Yes Amio, -bloc Amio, -bloc
Yes No Yes None None
Yes Yes No None Amio, -bloc*
Yes Yes Yes Flec, Mex Mex, Proc
No Yes Yes Mex Mex, Proc
Yes Yes Yes None None
Yes No Yes None -bloc
No Yes Yes -bloc -bloc
Yes No Yes None None
Yes No No None -bloc*
Yes Yes Yes None -bloc
Yes Yes Yes -bloc, Flec -bloc, Flec
Yes Yes Yes -bloc, Flec Amio
No Yes NA† Amio —
No Yes Yes None None
No Yes Yes None -bloc
Yes Yes No Mex Mex*
No Yes Yes Sot Sot
Yes No Yes None None
Yes Yes Yes Sot, -bloc Sot, Flec, -bloc
No No Yes Prop Prop
Yes Yes Yes Sot Sot, Met
Yes No Yes None -bloc
ion of this procedure. Follow-up was not possible.
eta-blocker; CCB  calcium channel blocker; Conv  conventional; Coum  Coumadin; Flec 
cainamide; Rec  recurrence; Sot  sotalol; VT  ventricular tachycardia.ecurr
re an
ted
mplicatrocedures.
p
t
a
p
t
T
d
g
t
d
r
p
L
t
3
a
d
d
(
f
a
V
t
s
s
r
c
p
2
o
a
o
1
r
p
d
d
b
436 Dalal et al. JACC Vol. 50, No. 5, 2007
VT Ablation in ARVD/C July 31, 2007:432–40The only major complication in this patient series was 1
rocedure-related death in a 33-year-old male patient (Pa-
ient #16, Table 3). He had undergone 2 previous attempts
t RFA, which were partially successful. Each of these
rocedures was followed by recurrent incessant VT. At the
hird RFA procedure, a highly unstable VT was induced.
his patient became severely hypotensive during the proce-
ure. Because of concern for cardiac tamponade, an emer-
ent thoracotomy was performed. No bleeding or cardiac
amponade was present. The patient was resuscitated but
ied of postoperative pulmonary complications. No perfo-
ation was reported in association with this or any other
rocedure in this group of patients.
ong-term follow-up. The follow-up duration between
he first ablation procedure and the last censoring was 32 
6 months (range 1 day to 12 years). The time to recurrence
fter each ablation procedure was 8  10 months (range 1
ay to 44 months). The RFA procedure that resulted in
eath of the patient was not included in the follow-up.
During follow-up, recurrence of VT occurred after 40
85%) of the 47 RFA procedures. Recurrence during
ollow-up after at least 1 of the RFA procedures occurred in
ll but 1 of the 24 patients. Four of these patients developed
T storms during follow-up. Of these patients, 2 were
reated with pharmacotherapy with control of their VT
torm and 2 underwent repeat RFA procedures. Figure 1
hows the survival analysis demonstrating cumulative VT
ecurrence-free survival in the entire study population. The
umulative VT recurrence-free survival after a single RFA
rocedure was 75% at 1.5 month, 50% at 5 months, and
5% at 14 months of follow-up. The cumulative incidence
f VT recurrence after a single procedure was 64%, 75%,
nd 91% at the end of 1, 2, and 3 years. The incidence rate
Figure 1 Survival Free of Ventricular Tachycardia Recurrence
Survival analysis showing the overall cumulative ventricular tachycardia recur-
rence-free survival in the entire study population. The table below the graph
represents the number of events during each interval indicated on the X axis
and the number of patients at risk at the beginning of that interval.f VT recurrence was 0.88 (95% confidence interval 0.39 to
.19) episodes per person-year.
There was no significant difference in the cumulative VT
ecurrence-free survival between patients who had complete
rocedural success, partial procedural success, and proce-
ural failure (Fig. 2). Similarly, there was no significant
ifference in the cumulative VT recurrence-free survival
etween patients in whom a 3-dimensional electroanatomi-
Figure 2 Survival Free of VT
Recurrence by Procedural Success
Survival analysis showing the comparison in the cumulative ventricular tachy-
cardia (VT) recurrence-free survival among patients undergoing complete proce-
dural success, partial procedural success, and procedural failure for ablation of
VT. The table below the graph represents the number of events during each
interval indicated on the X axis and the number of patients at risk at the begin-
ning of that interval.
Figure 3 Survival Free of VT
Recurrence by Mapping Technique
Survival analysis showing the comparison in the cumulative ventricular tachy-
cardia (VT) recurrence-free survival between patients undergoing the ablation
process using 3-dimensional (3D) electroanatomical mapping and combination
of the traditional mapping techniques. The table below the graph represents
the number of events during each interval indicated on the X axis and the num-
ber of patients at risk at the beginning of that interval.
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July 31, 2007:432–40 VT Ablation in ARVD/Cal approach was used and those in whom a traditional
pproach was used for mapping the VT (Fig. 3). Finally, the
umulative incidence of VT after the repeat procedures did
ot differ significantly from that after the first procedure
Fig. 4). The incidence rate of VT after the first procedure
1.00, 95% confidence interval 0.56 to 1.82 episodes/year)
lso was not significantly different from the incidence rate
fter the subsequent procedures (1.37, 95% confidence
nterval 0.88 to 2.12 episodes/year) (p  NS). During
ollow-up, 2 patients underwent heart transplantation
ecause of incessant VT, resulting in repeated ICD
nterventions.
iscussion
ain findings. Our results show that catheter ablation of
T in patients with ARVD/C is associated with a high rate
f recurrence and that acute procedural success is not
redictive of freedom from recurrence. Furthermore, the
esults are unaltered despite the extent of ablation or the
erformance of repeated attempts at ablation in the same
atient. Recurrence rates were similar regardless of whether
he initial ablation procedure was defined as total success,
artial success, or failure. The use of electroanatomical
apping systems to guide ablation of hemodynamically
nstable VTs with a substrate-based ablation strategy did
ot impact the rate of VT recurrence during follow-up.
RVD/C. ARVD/C is a complex arrhythmogenic disor-
er characterized by gradual loss of myocytes and replace-
ent by fatty and fibrous tissue. It leads to dilation of the
V and impaired cardiac function. Progression of ARVD/C
Figure 4 Survival Free of VT
Recurrence by Repetition of RFA Procedure
Survival analysis showing the comparison in the cumulative ventricular tachy-
cardia (VT) recurrence-free survival between patients undergoing first and sub-
sequent catheter ablation procedures. The table below the graph represents
the number of events during each interval indicated on the X axis and the num-
ber of patients at risk at the beginning of that interval. RFA  radiofrequency
catheter ablation.s characterized by progressive structural abnormalities of phe RV and subsequent signs of heart failure, and the
ncreased frequency and/or severity of ventricular arrhyth-
ias. Sustained ventricular arrhythmias lead to significant
ortality in patients with ARVD/C (4,24).
Recent evidence suggests that typical ARVD/C is a
isease of the cardiac desmosome. Desmosomes are special-
zed cadherin-based cell–cell adhesion structures abundant
n cardiac muscle and skin epidermis (7). Mutations in 1 or
ore desmosomal proteins, including desmoglein-2
25,26), desmoplakin (27–29), desmocollin-2 (30), junc-
ional plakoglobin (31,32), and plakophilin-2 (33–36) have
een identified in patients with ARVD/C. Mechanisms by
hich the affected desmosomes cause myocytes apoptosis,
brogenesis, and adipogenesis, thus leading to impaired RV
unction and increased arrhythmogenicity, have been shown
n vitro and in animal models (37). The effect of age and
xercise on disease progression at the desmosomal level has
lso been shown in a mouse model (38). These important
ew developments into the mechanism of ARVD/C help
xplain the diffuse and progressive nature of ARVD/C.
hey may also help explain the limited efficacy of catheter
blation reported in this study.
rior studies. Fontaine et al. (12,13,15) are credited with
ioneering the development of catheter ablation for treat-
ent of patients with ARVD/C. They initially used DC
hock energy with an approach referred to as fulguration,
nd more recently have used radiofrequency energy. Their
ioneering studies showed that catheter ablation of VT in
atients with ARVD/C is feasible, but that repeat ablation
rocedures are commonly needed to achieve arrhythmia
ontrol (15).
There have been 5 prior reports of the outcome of
adiofrequency catheter ablation of VT in patients with
RVD/C. In 1998, Ellison et al. (14) reported the acute
nd long-term outcome of catheter ablation in 5 ARVD/C
atients. Of the 19 inducible VTs, 8 were rendered nonin-
ucible and 3 were modified to a longer cycle length.
uring a mean follow-up of 17 months, with 3 of these
atients continuing antiarrhythmic therapy, none of these
atients had recurrent VT. In 2003, Reithmann et al. (16)
eported their experience with VT ablation using an elec-
roanatomical mapping system in 5 patients with ARVD/C.
he clinical VT was successfully ablated in 4 of these
atients, with 1 patient rendered completely noninducible.
uring a mean follow-up of 7  3 months, with amioda-
one continued in 3 patients, 60% of patients were free of
ecurrent VT. More recently, there have been 2 studies of
atheter ablation of VT in patients with ARVD/C. Both of
hese studies used an electroanatomical mapping system to
llow substrate-based ablation strategy for hemodynamically
nstable VT. Marchlinski et al. (18) described their expe-
ience with catheter ablation in 19 patients with an RV
yopathy who underwent 1 (n  6) or more (n  13)
ttempts at catheter ablation. Acute success, defined as the
bsence of all inducible VTs, was achieved in 14 (74%) of 19
atients. During a mean follow-up of 27  22 months, 17
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VT Ablation in ARVD/C July 31, 2007:432–4089%) of 19 patients were free of recurrent VT. Whether
hese patients met Task Force criteria for ARVD/C is
nclear. However, it is notable that nearly half of these
atients had possible biventricular disease with a left ven-
ricular ejection fraction 45% in 10 (48%) of the 21
atients. It is also unclear whether antiarrhythmic medica-
ions were used in this patient population because no details
n the use of antiarrhythmic drugs were included in this
eport. It is also notable that in this series repeat ablation
rocedures were required in 68% of patients, resulting in a
uch lower single-procedure efficacy of catheter ablation.
erma et al. (17) reported their experience with catheter
blation in 22 patients with ARVD/C, each of whom had
emodynamically unstable VT. Acute success with no
nducible VT at the end of the procedure was achieved in 18
82%) patients, with VT recurrence rates of 23%, 27%, and
7% at 1, 2, and 3 years, respectively. In this study, patients
emained on their antiarrhythmic therapy after the catheter
blation procedure.
atheter ablation results. The results of this study provide
ew insights into the acute and long-term efficacy of
atheter ablation of VT in patients with ARVD/C. Perhaps
he most striking finding is the extremely high rate of
ecurrent VT after catheter ablation in this patient popula-
ion, with 75% of patients experiencing a recurrence within
4 months of follow-up. This high rate of recurrence of VT
s distinctly different than that reported by Ellison et al. (14)
nd Marchlinski et al. (18), but somewhat similar to the
onsiderable recurrence rate note in the reports by Re-
thmann et al. (16) and Verma et al. (17). Reithmann et al.
16) reported a 40% recurrence rate during a mean
ollow-up of 7 months, and Verma et al. (17) reported a
ecurrence rate of 47% at 3 years of follow-up.
There are a number of potential explanations for why our
ncidence of VT during follow-up is higher than in other
eports. First, this study reflected the outcomes of a series of
RVD/C patients who underwent catheter ablation in a large
umber of electrophysiological laboratories throughout the
ountry. In contrast, all prior reports of catheter ablation of VT
n patients with ARVD/C have been published by referral
nstitutions with a particular interest in catheter ablation of VT
12–18). This difference is important because the results of this
tudy are more likely to be reflective of the outcomes that can
e achieved in widespread clinical practice. Second, this study
ncluded only patients who met the strict Task Force criteria
or ARVD/C. Earlier studies have generally not used the Task
orce criteria for ARVD/C, which were published in 1994, as
riteria for enrollment in their studies (19). Of particular note
s the recent study by Marchlinski et al. (18). The patients in
his series were quite atypical for patients with ARVD/C in
hat 10 of 21 patients had significant LV dysfunction with an
jection fraction of 45% or less. In contrast, no patient in our
eries had significant LV dysfunction. Third, this study re-
orted the outcome of all VT ablation procedures. This
ontrasts distinctly with the report byMarchlinski et al. (18), in
hich 68% patients underwent a second ablation procedure. fhis suggests that the long-term single-procedure success rate
n this series was 35%. The inclusion of repeat ablation
rocedures therefore clouds the true rate of recurrence of VT
xperienced by patients reported in this study. And finally,
ifferent ablation strategies were used in patients in this series
s compared with those in prior trials. This is particularly true
or the 2 most recent series by Marchlinski et al. (18) and
erma et al. (17), who have pioneered the technique of
ubstrate ablation for treatment of unmappable VTs in patients
ith ARVD/C. Whereas an electroanatomical mapping sys-
em was used in only 10 of the 48 ablation procedures in this
eries, an electroanatomical mapping system was used for all
blation procedures in these 2 recent series. Although use of an
lectroanatomical approach in our series did not impact long-
erm efficacy, it is possible that a substrate-based ablation
trategy may have higher efficacy than conventional ablation
trategies.
tudy limitations. Our study has several limitations. First,
here might be a significant variability in the performance
nd the accuracy of these procedures in different centers,
nd results may not be reflective of any single center.
owever, in the absence of a prospective multicenter study,
n which all treating electrophysiologists are trained to
erform procedures using a standard protocol, this is the
est alternative for evaluating the true success of these
rocedures as seen in clinical practice. Second, we did not
eport the frequency of VT episodes before and after each
atheter ablation procedure because not all patients had
CDs implanted for a consistent period before catheter
blation of VT. In many patients, ICD implantation was
erformed at the time of or subsequent to the initial ablation
rocedure. And third, the staggered entry survival analysis
ay have been inadequate to discern the differences in
ecurrence associated with mapping techniques, procedural
uccess, and repetition of catheter ablation procedures be-
ause observations in subgroups created by repetition of the
FA procedure were not independent.
linical implications and conclusions. The results of this
tudy, combined with those of prior studies, have several
bvious and immediate clinical implications. First, the very
igh rate of VT recurrence reported in this study and prior
tudies of catheter ablation of VT in ARVD/C patients makes
t clear that catheter ablation of VT in ARVD/C patients
annot and should not be considered curative. Although the
recise indications for ICD implantation in ARVD/C are not
ell established, we recommend ICD implantation for all
atients who meet the strict Task Force criteria for ARVD/C
11). Second, the results of this and other studies of catheter
blation of VT in patients with ARVD/C call into question
he early use of catheter ablation as an effective antiarrhythmic
trategy in these patients. Although there is some anecdotal
vidence to suggest that catheter ablation of VT may decrease
he frequency of VT episodes and appropriate ICD shocks in
his patient population, this has not been well studied. In fact,
here have been no large studies that have closely examined the
requency of ICD shocks before and after catheter ablation of
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July 31, 2007:432–40 VT Ablation in ARVD/CT in ARVD/C patients. Even if these data were available,
he results may reflect the clustering of VT episodes. In this
egard, it is notable that a recent study reported that ARVD/C
atients with “VT storm” all responded to treatment with
ntiarrhythmic drugs (39). It is clear that further studies will be
eeded to determine the clinical role of catheter ablation of VT
n patients with ARVD/C. Until these data are available, we
ould recommend that catheter ablation of VT in patients
ith ARVD/C only be used as a palliative procedure to reduce
he frequency of VT episodes, particularly after failure of 1 or
ore antiarrhythmic drugs. Moreover, we would recommend
hat these procedures be performed at centers highly experi-
nced with catheter ablation of ventricular arrhythmias.
eprint requests and correspondence: Dr. Hugh Calkins, 600
orth Wolfe Street, Carnegie 530, Baltimore, Maryland 21287.
-mail: hcalkins@jhmi.edu.
EFERENCES
1. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular
dysplasia: a report of 24 adult cases. Circulation 1982;65:384–98.
2. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyop-
athy and sudden death in young people. N Engl J Med 1988;318:
129–33.
3. Hulot JS, Jouven X, Empana JP, et al. Natural history and risk strati-
fication of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
Circulation 2004;110:1879–84.
4. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular
dysplasia: a United States experience. Circulation 2005;112:3823–32.
5. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection
of myocardial fibrosis in arrhythmogenic right ventricular cardiomy-
opathy using delayed-enhancement magnetic resonance imaging. J Am
Coll Cardiol 2005;45:98–103.
6. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic
manifestations of arrhythmogenic right ventricular cardiomyopathy/
dysplasia: a multicenter study. J Am Coll Cardiol 1997;30:1512–20.
7. Garrod DR. Desmosomes and hemidesmosomes. Curr Opin Cell Biol
1993;5:30–40.
8. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-
defibrillator therapy for prevention of sudden death in patients with
arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circula-
tion 2003;108:3084–91.
9. Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/
defibrillator therapy in arrhythmogenic right ventricular cardiomyop-
athy: single-center experience of long-term follow-up and complica-
tions in 60 patients. Circulation 2004;109:1503–8.
0. Roguin A, Bomma CS, Nasir K, et al. Implantable cardioverter-
defibrillators in patients with arrhythmogenic right ventricular dyspla-
sia/cardiomyopathy. J Am Coll Cardiol 2004;43:1843–52.
1. Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate
implantable defibrillator therapies in patients with arrhythmogenic
right ventricular dysplasia. Heart Rhythm 2005;2:1188–94.
2. Fontaine G, Frank R, Rougier I, et al. Electrode catheter ablation of
resistant ventricular tachycardia in arrhythmogenic right ventricular
dysplasia: experience of 13 patients with a mean follow-up of 45
months. Eur Heart J 1989;10 Suppl D:74–81.
3. Fontaine G, Frank R, Rougier I, et al. Electrode catheter ablation of
resistant ventricular tachycardia in arrhythmogenic right ventricular
dysplasia: experience of 15 patients with a mean follow-up of 45
months. Heart Vessels 1990;5:172–87.
4. Ellison KE, Friedman PL, Ganz LI, et al. Entrainment mapping and
radiofrequency catheter ablation of ventricular tachycardia in right
ventricular dysplasia. J Am Coll Cardiol 1998;32:724–8.
5. Fontaine G, Tonet J, Gallais Y, et al. Ventricular tachycardia catheter
ablation in arrhythmogenic right ventricular dysplasia: a 16-year
experience. Curr Cardiol Rep 2000;2:498–506.6. Reithmann C, Hahnefeld A, Remp T, et al. Electroanatomical
mapping of endocardial right ventricular activation as a guide for
catheter ablation in patients with arrhythmogenic right ventricular
dysplasia. Pacing Clin Electrophysiol 2003;26:1308–16.
7. Verma A, Kilicaslan F, Schweikert RA, et al. Short- and long-term
success of substrate-based mapping and ablation of ventricular tachy-
cardia in arrhythmogenic right ventricular dysplasia. Circulation 2005;
111:3209–16.
8. Marchlinski FE, Zado E, Dixit S, et al. Electroanatomical substrate
and outcome of catheter ablative therapy for ventricular tachycardia in
setting of right ventricular cardiomyopathy. Circulation 2004;110:
2293–8.
9. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic
right ventricular dysplasia/cardiomyopathy. Task Force of the Work-
ing Group Myocardial and Pericardial Disease of the European
Society of Cardiology and of the Scientific Council on Cardiomyop-
athies of the International Society and Federation of Cardiology. Br
Heart J 1994;71:215–8.
0. Stevenson WG, Khan H, Sager P, et al. Identification of reentry
circuit sites during catheter mapping and radiofrequency ablation of
ventricular tachycardia late after myocardial infarction. Circulation
1993;88:1647–70.
1. Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocar-
dial electrophysiological substrate in patients with nonischemic car-
diomyopathy and monomorphic ventricular tachycardia. Circulation
2003;108:704–10.
2. Marchlinski FE, Callans DJ, Gottlieb CD, et al. Linear ablation
lesions for control of unmappable ventricular tachycardia in patients
with ischemic and nonischemic cardiomyopathy. Circulation 2000;
101:1288–96.
3. Dixit S, Callans DJ. Mapping for ventricular tachycardia. Card
Electrophysiol Rev 2002;6:436–41.
4. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and
gross and microscopic observations in a series of 200 cases of sudden
death associated with arrhythmogenic right ventricular cardiomyopa-
thy and/or dysplasia. Circulation 2003;108:3000–5.
5. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene
are associated with arrhythmogenic right ventricular cardiomyopathy.
Circulation 2006;113:1171–9.
6. Awad MM, Dalal D, Cho E, et al. DSG2 mutations contribute to
arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J
Hum Genet 2006;79:136–42.
7. Alcalai R, Metzger S, Rosenheck S, et al. A recessive mutation in
desmoplakin causes arrhythmogenic right ventricular dysplasia, skin
disorder, and woolly hair. J Am Coll Cardiol 2003;42:319–27.
8. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human
desmoplakin domain binding to plakoglobin causes a dominant form
of arrhythmogenic right ventricular cardiomyopathy. Am J Hum
Genet 2002;71:1200–6.
9. Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families
with arrhythmogenic right ventricular cardiomyopathy caused by
dominant desmoplakin mutations. Eur Heart J 2005;26:1666–75.
0. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular
dysplasia/cardiomyopathy associated with mutations in the desmo-
somal gene desmocollin-2. Am J Hum Genet 2006;79:978–84.
1. McKoy G, Protonotarios N, Crosby A, et al. Identification of a
deletion in plakoglobin in arrhythmogenic right ventricular cardiomy-
opathy with palmoplantar keratoderma and woolly hair (Naxos dis-
ease). Lancet 2000;355:2119–24.
2. Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-
phenotype assessment in autosomal recessive arrhythmogenic right
ventricular cardiomyopathy (Naxos disease) caused by a deletion in
plakoglobin. J Am Coll Cardiol 2001;38:1477–84.
3. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal
protein plakophilin-2 are common in arrhythmogenic right ventricular
cardiomyopathy. Nat Genet 2004;36:1162–4.
4. Syrris P, Ward D, Asimaki A, et al. Clinical expression of
plakophilin-2 mutations in familial arrhythmogenic right ventricular
cardiomyopathy. Circulation 2006;113:356–64.
5. Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmo-
genic right ventricular dysplasia/cardiomyopathy associated with mu-
tations in plakophilin-2. Circulation 2006;113:1641–9.
33
3
3
440 Dalal et al. JACC Vol. 50, No. 5, 2007
VT Ablation in ARVD/C July 31, 2007:432–406. van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2
mutations are the major determinant of familial arrhythmogenic right
ventricular dysplasia/cardiomyopathy. Circulation 2006;113:1650–8.
7. Garcia-Gras E, Lombardi R, Giocondo MJ, et al. Suppression of
canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapit-
ulates phenotype of arrhythmogenic right ventricular cardiomyopathy.
J Clin Invest 2006;116:2012–21.8. Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent
development of arrhythmogenic right ventricular cardiomyopathy in
heterozygous plakoglobin-deficient mice. Circulation 2006;114:1799–
806.
9. Strohmer B, Schernthaner C, Pichler M. Multiple appropriate and
spurious defibrillator shocks in a patient with right ventricular cardio-
myopathy. Int J Cardiol 2005;102:363–6.
